A Proof-of-Concept Trial to Study the Safety and Activity of Linvoseltamab in Participants With Smoldering Multiple Myeloma at High Risk of Developing Multiple Myeloma

KEY Inclusion Criteria:

1. High-risk SMM diagnosis within 5 years of study enrollment

2. Eastern Cooperative Oncology Group (ECOG) performance status ≤1

3. Adequate hematologic and hepatic function, as described in the protocol

4. Estimated glomerular filtration rate ≥30 mL/min/1.73 m^2

KEY Exclusion Criteria:

1. Evidence of myeloma defining events *SLiM CRAB, as described in the protocol

*SLiM (greater than or equal to Sixty percent clonal plasma cells in the bonemarrow, involved/uninvolved free Light chain ratio of ≥100 with the involved freelight chain (FLC) being ≥100 mg/L, MRI with >1 focal lesion) CRAB (hyperCalcemia,Renal insufficiency, Anemia, or lytic Bone lesions)

2. Diagnosis of systemic light chain amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), soft tissue plasmacytoma, or symptomatic multiplemyeloma

3. Clinically significant cardiac or vascular disease within 3 months of studyenrollment, as described in the protocol

4. Any infection requiring hospitalization or treatment with IV anti-infectives within 28 days of first dose of study drug

5. Uncontrolled human immunodeficiency virus (HIV), hepatitis B virus (HBV), orhepatitis C virus (HCV) infection; or other uncontrolled infection or unexplainedsigns of infection

6. History of severe allergic reaction attributed to compounds with a similar chemicalor biologic composition as the study drug or excipient

NOTE: Other protocol defined inclusion/exclusion criteria apply